×
VV116 as a potential treatment for COVID-19.
https://doi.org/10.1080/14656566.2023.2193668
Expert Opinion on Pharmacotherapy; McCarthy MW

Mar 19th, 2023 - VV116 is a chemically-modified version of the antiviral remdesivir with oral bioavailability and potent activity against SARS-CoV-2. The optimal treatment of standard-risk outpatients who develop mild-to-moderate COVID-19 is controversial. While several therapeutic are currently recommended, including nirmatrelvir-ritonavir (Paxlovid), molnupiravir, and remdesivir, these treatments have substan...

Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventati...
https://doi.org/10.1080/14760584.2023.2191716
Expert Review of Vaccines; Tan TT, Ng HJ et. al.

Mar 16th, 2023 - Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including administration of booster doses, continues to be the most effective method for controlling COVID-19-related complications including progression to severe illness and death.However, there is mounting evidence that more needs to be done to protect individuals with compromised immune function. Here, we revi...

Assessing the effects of therapeutic combinations on SARS-CoV-2 infected patient outcom...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997963
PloS One; Moradi H, Bunnell HT et. al.

Mar 10th, 2023 - The COVID-19 pandemic has demonstrated the need for efficient and comprehensive, simultaneous assessment of multiple combined novel therapies for viral infection across the range of illness severity. Randomized Controlled Trials (RCT) are the gold standard by which efficacy of therapeutic agents is demonstrated. However, they rarely are designed to assess treatment combinations across all relev...

Isolation and Characterization of Anti-Mycobacterial Natural Products from a Petrosia s...
https://doi.org/10.1021/acs.jnatprod.2c01003
Journal of Natural Products; Khatri Chhetri B, Bhanushali R et. al.

Mar 8th, 2023 - Tuberculosis (TB) is a dreadful infectious disease and a leading cause of mortality and morbidity worldwide, second in 2020 only to severe acute respiratory syndrome 2 (SARS-Cov-2). With limited therapeutic options available and a rise in multidrug-resistant tuberculosis cases, it is critical to develop antibiotic drugs that display novel mechanisms of action. Bioactivity-guided fractionation e...

Isolation, characterization, therapeutic potency, and genomic analysis of a novel bacte...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955523
Annals of Clinical Microbiology and Antimicrobials; Mohammadi M, Saffari M et. al.

Feb 25th, 2023 - Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a significant clinical problem, given the lack of therapeutic options. The CRKP strains have emerged as an essential worldwide healthcare issue during the last 10 years. Global expansion of the CRKP has made it a significant public health hazard. We must consider to novel therapeutic techniques. Bacteriophages are potent restorative cases aga...

Insight into Oncogenic Viral Pathways as Drivers of Viral Cancers: Implication for Effe...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955780
Current Oncology (Toronto, Ont.); Elkhalifa AME, Nabi SU et. al.

Feb 25th, 2023 - As per a recent study conducted by the WHO, 15.4% of all cancers are caused by infectious agents of various categories, and more than 10% of them are attributed to viruses. The emergence of COVID-19 has once again diverted the scientific community's attention toward viral diseases. Some researchers have postulated that SARS-CoV-2 will add its name to the growing list of oncogenic viruses in the...

Vaccination and treatment options for SARS-CoV2 infection affecting lactation and breas...
https://doi.org/10.1016/j.siny.2023.101425
Seminars in Fetal & Neonatal Medicine; Chen MJ, Cheema R et. al.

Feb 23rd, 2023 - The COVID-19 pandemic has posed considerable challenges to the health of lactating individuals. Vaccination remains one of the most important strategies for prevention of moderate to severe COVID-19 infection and is associated with protective benefits for lactating individuals and their breastfed infants with overall mild side effects. The current recommendations for COVID-19 treatment in lacta...

A Propensity-Matched Cohort Assessing Impact of a Neutralizing Monoclonal Antibody in M...
https://doi.org/10.1177/08850666231155822
Journal of Intensive Care Medicine; Abbas M, Farhat N et. al.

Feb 14th, 2023 - Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoaV-2) is responsible for the coronavirus disease 2019 (COVID-19) pandemic. In randomized clinical trials, patients who were treated with the anti-spike monoclonal antibody bamlanivimab had fewer COVID-19-related hospitalizations or emergency department (ED) visits than the control group. Methods: A retrospective cohort was asse...

Viral T-cell epitopes - Identification, characterization and clinical application.
https://doi.org/10.1016/j.smim.2023.101725
Seminars in Immunology; Schroeder SM, Nelde A et. al.

Jan 28th, 2023 - T-cell immunity, mediated by CD4+ and CD8+ T cells, represents a cornerstone in the control of viral infections. Virus-derived T-cell epitopes are represented by human leukocyte antigen (HLA)-presented viral peptides on the surface of virus-infected cells. They are the prerequisite for the recognition of infected cells by T cells. Knowledge of viral T-cell epitopes provides on the one hand a di...

Anti-inflammatory and antioxidant activities of Gymnema Sylvestre extract rescue acute ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864508
Inflammopharmacology Jangam A, Tirunavalli SK et. al.

Jan 21st, 2023 - Acute respiratory distress syndrome (ARDS) is one of the major causes of mortality in COVID-19 patients, due to limited therapeutic options. This prompted us to explore natural sources to mitigate this condition. Gymnema Sylvestre (GS) is an ancient medicinal plant known to have various therapeutic effects. This investigation examined the therapeutic effect of hydroalcoholic extract of Gymnema ...

Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary head...
https://doi.org/10.1177/03331024221131337
Cephalalgia : an International Journal of Headache; Caronna E, van den Hoek TC et. al.

Jan 7th, 2023 - The objective is to summarize the knowledge on the epidemiology, pathophysiology and management of secondary headache attributed to SARS-CoV-2 infection and vaccination; as well as to delineate their impact on primary headache disorders. This is a narrative review of the literature regarding primary and secondary headache disorders in the setting of COVID-19 pandemic. We conducted a literature ...

Bispecific antibodies and its applications: a novel approach for targeting SARS-Cov-2.
https://doi.org/10.1515/jbcpp-2022-0068
Journal of Basic and Clinical Physiology and Pharmacology; Shukla AK, Misra S

Jan 7th, 2023 - The COVID-19 pandemic remains a severe global threat, with the world engulfed in the struggle against the disease's second or third waves, which are approaching frightening proportions in terms of cases and mortality in many nations. Despite the critical need for effective therapy, there is still uncertainty about the optimal practices for treating COVID-19 with various pharmaceutical approache...

The potential impact of nanomedicine on COVID-19-induced thrombosis.
https://doi.org/10.1038/s41565-022-01270-6
Nature Nanotechnology; Russell P, Esser L et. al.

Dec 20th, 2022 - Extensive reports of pulmonary embolisms, ischaemic stroke and myocardial infarctions caused by coronavirus disease 2019 (COVID-19), as well as a significantly increased long-term risk of cardiovascular diseases in COVID-19 survivors, have highlighted severe deficiencies in our understanding of thromboinflammation and the need for new therapeutic options. Due to the complexity of the immunothro...

Prevalence of Long-COVID Among Low-Income and Marginalized Groups: Evidence From Israel.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742204
International Journal of Public Health; Heller O, Chun Y et. al.

Dec 16th, 2022 - Objective: To identify the socioeconomic and demographic factors associated with the prevalence of self-reported long-COVID symptoms. Method: We examined the association between acute-COVID (SARS-CoV-2) and long-COVID symptoms, by a cross-sectional analysis of data obtained on a prospective online-survey, conducted from November to December 2021 on a nationally-representative sample of the Isra...

Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746792
The Journal of Allergy and Clinical Immunology; Tangye SG,

Dec 16th, 2022 - Since the arrival of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019, its characterization as a novel human pathogen, and the resulting coronavirus disease 2019 (COVID-19) pandemic, over 6.5 million people have died worldwide-a stark and sobering reminder of the fundamental and nonredundant roles of the innate and adaptive immune systems in host defense against eme...

Severe COVID-19-associated myocarditis with cardiogenic shock - management with assist ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742039
BMC Anesthesiology; Noone S, Flinspach AN et. al.

Dec 13th, 2022 - Primary viral myocarditis associated with severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) infection is a rare diagnosis. We report the case of an unvaccinated, healthy patient with cardiogenic shock in the context of a COVID-19-associated myocarditis and therapy with simultaneous veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and percutaneous left ventricular decompress...

Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729583
Antiviral Research; Pérez-Vargas J, Shapira T et. al.

Dec 13th, 2022 - The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global public health crisis. The reduced efficacy of therapeutic monoclonal antibodies against emerging SARS-CoV-2 variants of concern (VOCs), such as omicron BA.5 subvariants, has underlined the need to explore a novel spectrum of antivirals that are effective against existing and evolving ...

Prevention and treatment of COVID-19 in patients with benign and malignant blood disord...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398935
Best Practice & Research. Clinical Haematology; Saade EA, Hojat LS et. al.

Dec 10th, 2022 - Patients with moderate to severe immunosuppression, a condition that is common in many hematologic diseases because of the pathology itself or its treatment, are at high risk for COVID-19 and its complications. While empirical data are sometimes conflicting, this heightened risk has been confirmed in multiple well-done studies for patients with hematologic malignancies, particularly those with ...

Fomepizole should not be used more liberally in paracetamol overdose.
https://doi.org/10.1111/bcp.15596
British Journal of Clinical Pharmacology; Dear JW

Dec 7th, 2022 - Fomepizole is a promising new treatment for preventing liver injury following paracetamol (acetaminophen) overdose. However, we need robust clinical trials to be performed to demonstrate its effect on clinical outcomes that are important to our patients and important to healthcare providers. Until such trials are performed, the toxicology community should learn the lessons from the COVID pandem...

Exploring new antiviral targets for influenza and COVID-19: Mapping promising hot spots...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674405
Virology Figueiredo-Nunes I, Trigueiro-Louro J et. al.

Dec 5th, 2022 - Influenza and COVID-19 are infectious respiratory diseases that represent a major concern to public health with social and economic impact worldwide, for which the available therapeutic options are not satisfactory. The RdRp has a central role in viral replication and thus represents a major target for the development of antiviral approaches. In this study, we focused on Influenza A virus PB1 p...